Boston Pharmaceuticals

EASL 2023 – Biomarkers back a new NASH player
EP Vantage
Mon, 06/26/23 - 09:32 am
NASH
89Bio
pefozafermin
Boston Pharmaceuticals
BOS-580
Ex-Novartis NASH drug clears clinical test, fueling Boston's pursuit of Akero, 89bio
Fierce Biotech
Wed, 06/21/23 - 10:51 am
Boston Pharmaceuticals
NASH
Novartis
Akero Therapeutics
89Bio
BOS-580
Boston Pharmaceuticals signs three-year agreement with GSK
Pharmaceutical Business Review
Fri, 03/19/21 - 10:46 am
GSK
Boston Pharmaceuticals
drug development
Novartis hands off NASH drug to biotech collaborator, also plans to build new Basel production unit
Endpoints
Tue, 09/1/20 - 11:05 am
Novarts
NASH
Boston Pharmaceuticals
BOS-580
Boston Pharma Doubles Pipeline with 2 Deals with Novartis and GSK
BioSpace
Wed, 10/3/18 - 11:58 am
Boston Pharmaceuticals
GSK
Novartis
Daiichi Sankyo hands off cancer drug to Boston Pharma
BioPharma Dive
Wed, 08/30/17 - 09:58 am
Boston Pharmaceuticals
Daiichi Sankyo
DS-5010
cancer